Company intelligence / Profile preview
Totient
United States
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Totient developed a computational and experimental platform to reconstruct fully human antibodies from patients with exceptional immune responses and to identify their tissue-specific antigens for potential use in cell therapies and other biologic therapeutics; there is no evidence of advanced clinical-stage programs at the time of acquisition by Absci in 2021.[1][2][4]
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Monoclonal antibodyBiologicCell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Viva Biotech (investment and collaboration partner)[2][1]
Beyond the preview
Go deeper on Totient.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Totient.